Nirubasini Paramalingam

Ms. Nirubasini Paramalingam

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2018 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
SJStephanie R. Johnson
Stephanie R. Johnson
JEJonathan J. Ellis
Jonathan J. Ellis
PLPaul J. Leo
Paul J. Leo
LALisa K. Anderson
Lisa K. Anderson
UGUma Ganti
Uma Ganti
EDEmma L. Duncan
Emma L. Duncan

29 June 2021 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
MBMarie-Anne Burckhardt
Marie-Anne Burckhardt
MAMary Binsu Abraham
Mary Binsu Abraham
JDJulie Dart
Julie Dart
GSGrant J. Smith
Grant J. Smith
NPNirubasini Paramalingam
Nirubasini Paramalingam
TJTimothy W. Jones
Timothy W. Jones
Objective: This study evaluated the efficacy of using a hybrid closed loop (HCL) system in restoring hypoglycemia awareness in individuals with impaired awareness of hypoglycemia (IAH). Research Design and Methods: Participants with IAH (Gold score ≥4) were recruited into a randomized crossover pilot study. They participated in two 8-week periods using a HCL system (Medtronic 670G™) (intervention) and standard insulin pump therapy (control). Hyperinsulinemic hypoglycemic clamp studies were undertaken at baseline and at the end of each study period for the evaluation of the counter-regulatory hormonal and symptomatic responses to hypoglycemia. Results: Seventeen participants (mean age [standard deviation] 35.8 years [11.2 years]) were included in the study. Peak epinephrine levels (median, interquartile range [IQR]) in response to hypoglycemia were similar postintervention and control periods; 234.7 pmol/L (109.2; 938.9) versus 188.3 pmol/L (133.7; 402.9), P = 0.233. However, both peak adrenergic and neuroglycopenic symptom scores were higher after intervention; 5.0 (4.5; 9.0) versus 4.0 (4.0; 5.5), P = 0.009, and 8.5 (6.0; 15.0) versus 6.5 (6.0; 7.0) P = 0.014, respectively. Self-reported hypoglycemia awareness improved: median (IQR) Gold score was 4.0 (3.0; 5.5) versus 5.5 (4.5; 6.0); intervention versus control, P = 0.033. Time spent <3.9 and <3.0 mmol/L was lower in the intervention group than in control, P = 0.002. Other patient-reported outcomes (hypoglycemia fear and diabetes treatment satisfaction) did not change. Conclusions: A short-term use of a HCL system failed to demonstrate an improvement in counter-regulatory hormonal responses. However, higher hypoglycemia symptom scores during controlled hypoglycemia, better self-reported hypoglycemia awareness, and less time spent in hypoglycemia suggest the potential benefits of a HCL system in people with IAH. Trial Registration: anzctr.org.au Identifier: ACTRN12616000909426.

20 January 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
NPNirubasini Paramalingam
Nirubasini Paramalingam
BKBarbara Keating
Barbara Keating
TCTarini Chetty
Tarini Chetty
PFPaul Albert Fournier
Paul Albert Fournier
WSWayne H. K. Soon
Wayne H. K. Soon
EDElizabeth Davis
Elizabeth Davis
Dietary protein causes dose-dependent hyperglycemia in individuals with type 1 diabetes (T1D). This study investigated the effect of consuming 50 g of protein on overnight blood glucose levels (BGLs) following late-afternoon moderate-intensity exercise. Six participants (3M:3F) with T1D, HbA1c 7.5 ± 0.8% (58.0 ± 8.7 mmol/mol) and aged 20.2 ± 3.1 years exercised for 45 min at 1600 h and consumed a protein drink or water alone at 2000 h, on two separate days. A basal insulin euglycemic clamp was employed to measure the mean glucose infusion rates (m-GIR) required to maintain euglycemia on both nights. The m-GIR on the protein and water nights during the hypoglycemia risk period and overnight were 0.27 ± 043 vs. 1.60 ± 0.66 mg/kg/min (p = 0.028, r = 0.63) and 0.51 ± 0.16 vs. 1.34 ± 0.71 mg/kg/min (p = 0.028, r = 0.63), respectively. Despite ceasing intravenous glucose infusion on the protein night, the BGLs peaked at 9.6 ± 1.6 mmol/L, with a hypoglycemia risk period mean of 7.8 ± 1.5 mmol/L compared to 5.9 ± 0.4 mmol/L (p = 0.028) on the water night. The mean plasma glucagon levels were 51.5 ± 14.1 and 27.2 ± 10.1 ng/L (p = 0.028) on the protein and water night, respectively. This suggests that an intake of protein is effective at reducing the post-exercise hypoglycemia risk, potentially via a glucagon-mediated stimulation of glucose production. However, 50 g of protein may be excessive for maintaining euglycemia.

30 July 2024 in JMIR Diabetes
Verified
Journal Article
Open access
VSVinutha B Shetty
Vinutha B Shetty
LFLeanne Fried
Leanne Fried
HRHeather C Roby
Heather C Roby
WSWayne H K Soon
Wayne H K Soon
RNRebecca Nguyen
Rebecca Nguyen
EDElizabeth Davis
Elizabeth Davis
Background: Blood glucose management around exercise is challenging for youth with type 1 diabetes (T1D). Previous research has indicated interventions including decision-support aids to better support youth to effectively contextualize blood glucose results and take appropriate action to optimize glucose levels during and after exercise. Mobile health (mHealth) apps help deliver health behavior interventions to youth with T1D, given the use of technology for glucose monitoring, insulin dosing, and carbohydrate counting. Objective: We aimed to develop a novel prototype mHealth app to support exercise management among youth with T1D, detail the application of a co-design process and design thinking principles to inform app design and development, and identify app content and functionality that youth with T1D need to meet their physical activity goals. Methods: A co-design approach with a user-centered design thinking framework was used to develop a prototype mHealth app “acT1ve” during the 18-month design process (March 2018 to September 2019). To better understand and respond to the challenges among youth with diabetes when physically active, 10 focus groups were conducted with youth aged 13-25 years with T1D and parents of youth with T1D. Thereafter, we conducted participatory design workshops with youth to identify key app features that would support individual needs when physically active. These features were incorporated into a wireframe, which was critically reviewed by participants. A beta version of “acT1ve” was built in iOS and android operating systems, which underwent critical review by end users, clinicians, researchers, experts in exercise and T1D, and app designers. Results: Sixty youth with T1D, 14 parents, 6 researchers, and 10 clinicians were engaged in the development of “acT1ve.” acT1ve included key features identified by youth, which would support their individual needs when physically active. It provided advice on carbohydrates and insulin during exercise, information on hypoglycemia treatment, pre- and postexercise advice, and an educational food guide regarding exercise management. “acT1ve” contained an exercise advisor algorithm comprising 240 pathways developed by experts in diabetes and exercise research. Based on participant input during exercise, acT1ve provided personalized insulin and carbohydrate advice for exercise lasting up to 60 minutes. It also contains other features including an activity log, which displays a complete record of the end users’ activities and associated exercise advice provided by the app’s algorithm for later reference, and regular reminder notifications for end users to check or monitor their glucose levels. Conclusions: The co-design approach and the practical application of the user-centered design thinking framework were successfully applied in developing “acT1ve.” The design thinking processes allowed youth with T1D to identify app features that would support them to be physically active, and particularly enabled the delivery of individualized advice. Furthermore, app development has been described in detail to help guide others embarking on a similar project. Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN12619001414101; https://tinyurl.com/mu9jvn2d

5 May 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
BKBarbara Keating
Barbara Keating
CSCarmel Elizabeth Smart
Carmel Elizabeth Smart
Amelia HarrayAmelia Harray
Amelia Harray
NPNirubasini Paramalingam
Nirubasini Paramalingam
GSGrant Smith
Grant Smith
EDElizabeth Davis
Elizabeth Davis
Context The pattern and quantity of insulin required for high-protein high-fat (HPHF) meals is not well understood. Objective This study aimed to determine the amount and delivery pattern of insulin required to maintain euglycemia for 5 hours after consuming a HPHF meal compared with a low-protein low-fat (LPLF) meal. Methods This randomized crossover clinical trial, conducted at 2 Australian pediatric diabetes centers, included 10 patients (12-21 years of age) with type 1 diabetes for ≥ 1 year. Participants were randomized to HPHF meal (60 g protein, 40 g fat) or LPLF meal (5 g protein, 5 g fat) with identical carbohydrate content (30 g). A modified insulin clamp technique was used to determine insulin requirements to maintain postprandial euglycemia for 5 hours. Total mean insulin requirements over 5 hours were measured. Results The total mean insulin requirements for the HPHF meal were significantly greater than for the LPLF meal (11.0 [CI 9.2, 12.8] units vs 5.7 [CI 3.8, 7.5] units; P = 0.001). Extra intravenous insulin was required for HPHF: 0 to 2 hours (extra 1.2 [CI 0.6, 1.6] units/h), 2 to 4 hours (extra 1.1 [CI 0.6, 1.6] units/h), and 4 to 5 hours (extra 0.6 [CI 0.1, 1.1] units/h) after the meal. There were marked inter-individual differences in the quantity of additional insulin (0.3 to 5 times more for HPHF) and the pattern of insulin delivery (0%-85% of additional insulin required in the first 2 hours). Conclusion The addition of protein and fat to a standardized carbohydrate meal almost doubled the mean insulin requirement, with most participants requiring half of the additional insulin in the first 2 hours.

19 August 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
Amelia HarrayAmelia Harray
Amelia Harray
SBSabrina Binkowski
Sabrina Binkowski
BKBarbara L Keating
Barbara L Keating
Michael HorowitzMichael Horowitz
Michael Horowitz
SSScott Standfield
Scott Standfield
EDElizabeth Davis
Elizabeth Davis
Context Dietary fat and protein impact postprandial hyperglycaemia in people with type 1 diabetes, but the underlying mechanisms are poorly understood. Glucoregulatory hormones are also known to modulate gastric emptying and may contribute to this effect. Objective Investigate the effects of fat and protein on glucagon like peptide (GLP-1), glucagon-dependent insulinotropic polypeptide (GIP) and glucagon secretion. Design Two cross-over euglycaemic insulin clamp clinical trials. Setting Two Australian paediatric diabetes centres. Participants 12-21years (n=21) with type 1 diabetes for ≥1year. Intervention(s) Participants consumed a low protein (LP) or high protein (HP) meal in Study 1, and low protein/low fat (LPLF) or high protein/high fat (HPHF) meal in Study 2, all containing 30g carbohydrate. An insulin clamp was used to maintain postprandial euglycaemia and plasma glucoregulatory hormones were measured every 30 minutes for 5-hours. Data from both cohorts (n=11,10) were analysed separately. Main Outcome Area under the curve of GLP-1, GIP and glucagon. Results Meals low in fat and protein had minimal effect on GLP-1, while there was sustained elevation after the HP (80.3±16.8pmol/L) vs LP (56.9±18.6), P=0.016, and HPHF (103.0±26.9) vs LPLF (69.5±31.9) meals, P=0.002. The prompt rise in GIP after all meals was greater after the HP (190.2±35.7pmol/L) vs LP (152.3±23.3), P=0.003, and HPHF (258.6±31.0) vs LPLF (151.7±29.4), P<0.001. A rise in glucagon was also seen in response to protein, HP (292.5±88.1pg/mL) vs LP (182.8±48.5), P=0.010. Conclusions The impact of fat and protein on postprandial glucose excursions may be mediated by the differential secretion of glucoregulatory hormones. Further studies to better understand these mechanisms may lead to improved personalised postprandial glucose management.